GSM5359418
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.500
- INTERFERON_GAMMA_RESPONSE+0.470
- TNFA_SIGNALING_VIA_NFKB+0.390
- IL6_JAK_STAT3_SIGNALING+0.330
- ALLOGRAFT_REJECTION+0.320
- APOPTOSIS+0.220
- INFLAMMATORY_RESPONSE+0.220
- KRAS_SIGNALING_UP+0.220
- HEME_METABOLISM+0.210
- TGF_BETA_SIGNALING+0.200
Top 10 suppressed
- E2F_TARGETS-0.530
- MYC_TARGETS_V2-0.470
- G2M_CHECKPOINT-0.390
- MYC_TARGETS_V1-0.340
- UNFOLDED_PROTEIN_RESPONSE-0.340
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.310
- MTORC1_SIGNALING-0.300
- DNA_REPAIR-0.270
- GLYCOLYSIS-0.240
- OXIDATIVE_PHOSPHORYLATION-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8943004 | — | — | 0.894 |
| 2 | TCGA-D8-A1JB-01A-11R-A13Q-07 | — | A | 0.890 |
| 3 | 98e49cc4-1040-4291-b975-da3e8fc3ddfc | — | — | 0.883 |
| 4 | BS_CS170P7T | pilocytic astrocytoma | — | 0.879 |
| 5 | DRR168509 | — | — | 0.862 |
| 6 | 20030005.Her2HRpos | — | A | 0.853 |
| 7 | SRR8518296 | — | A | 0.848 |
| 8 | SRR2932841 | — | — | 0.846 |
| 9 | DRR168552 | — | — | 0.845 |
| 10 | TCGA-MP-A4TJ-01A-51R-A262-07 | — | cohortA1 | 0.843 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.470 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.390 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.330 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.320 | Idelalisib | — uncovered |
| APOPTOSIS | 0.220 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.220 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.220 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.210 | Temsirolimus | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.160 | Idelalisib | — uncovered |
| COMPLEMENT | 0.140 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.120 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.120 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.090 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.080 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.060 | Inavolisib | — uncovered |
| COAGULATION | 0.010 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.010 | Remibrutinib | — uncovered |